Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients.
While non-small cell lung cancer is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly.
Queen’s University Belfast and Domainex are pleased to announce that their joint project team has successfully identified novel first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP.
UT Southwestern researchers have identified two proteins that act as gatekeepers to dampen a potentially life-threatening immune response to chronic infection.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Prophylactic cranial irradiation, a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer after initial therapy.
Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.
As far back as Ancient Greece, a sculptured physique has been heralded as the pinnacle of physical perfection. But now, researchers from Japan have found that increased muscle mass doesn't just make you look good, it could literally save your life.
Researchers at the University of Illinois at Chicago and Queensland University of Technology of Australia, have developed a device that can isolate individual cancer cells from patient blood samples. The microfluidic device works by separating the various cell types found in blood by their size.
Although molecular-targeted drugs have been known to show high efficacy to lung cancer patients, they also have limitations due to acquiring resistance to the drug used.
Despite rapid advances in targeted therapies for cancer, tumors commonly develop resistance to treatment. When resistance emerges, tumor cells continue to grow unchecked, despite all attempts to slow cancer progression.
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer.
A new form of cancer fighting drug has been developed using the principles of the “Trojan Horse”.
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form.
The Lung Cancer Master Protocol, the first precision medicine trial in lung cancer supported by the National Cancer Institute, part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers -- which make up about 85 percent of all lung cancer diagnoses in the U.S.
QIAGEN N.V. today announced that the Japanese Pharmaceuticals and Medical Device Agency has approved the therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer's VIZIMPRO (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent non-small cell lung cancer.
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.
According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chance of being alive 5 years later. For patients with stage IV disease, describing cancer that has spread to distant sites beyond the original tumor, that statistic drops to 2 percent.
The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or "knocking out" a gene in cancer tumors that helps the tumors develop resistance to the drugs.
The strategy for triggering the patient's own immune system to attack cancer, immunotherapy, is proving effective for more and more tumor types, although to varying degrees.